Rituximab combined to ACVBP (R-ACVBP) as a new inductive treatment followed by high-dose consolidative autotransplantation (HDC) for poor risk diffuse large B-cell lymphoma (DLBCL) in first-line.: Preliminary results on 119 patients of a GELA phase II study.

被引：2

作者：

Belhadi, Karim

Fitoussi, Olivier

Haioun, Corinne

Mounier, Nicolas

Lederlin, Pierre

Coiffier, Bertrand

Recher, Christian

Casasnovas, Olivier

Sebban, Catherine

Ferme, Christophe

Tilly, Herve

Gisselbrecht, Christian

机构：

[1] Hop Henri Mondor, Serv Hematol, F-94010 Creteil, France

[2] Polyclin Bordeuax Nord, Serv Oncol, Bordeaux, France

[3] Hop St Louis, Inst Hematol, Paris, France

[4] CHU Nancy Brabois, Serv Hematol, Vandoeuvre Les Nancy, France

[5] CHU Purpan, Serv Hematol, Toulouse, France

[6] CHU Dijon, Serv Hematol, Dijon, France

[7] Ctr Leon Berard, Serv Hematol, F-69373 Lyon, France

[8] Inst Gustave Roussy, Dept Med, Villejuif, France

[9] Ctr Henri Becquerel, Dept Hematol, F-76038 Rouen, France

来源：

关键词：

D O I：

10.1182/blood.V108.11.3049.3049

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3049

引用

页码：868A / 868A

页数：1